Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Rating of “Buy” by Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have received a consensus rating of “Buy” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $131.86.

LNTH has been the topic of a number of recent analyst reports. Redburn Atlantic began coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. Truist Financial restated a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. JMP Securities decreased their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. Finally, The Goldman Sachs Group initiated coverage on Lantheus in a research note on Wednesday. They issued a “buy” rating and a $143.00 price objective for the company.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Farallon Capital Management LLC grew its holdings in Lantheus by 53.7% during the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock valued at $182,999,000 after buying an additional 796,000 shares during the last quarter. Groupama Asset Managment acquired a new position in shares of Lantheus in the third quarter worth $439,000. Point72 Asset Management L.P. purchased a new stake in shares of Lantheus in the second quarter valued at $26,794,000. Janus Henderson Group PLC boosted its stake in shares of Lantheus by 7.7% during the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock valued at $393,844,000 after acquiring an additional 257,022 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA purchased a new stake in Lantheus during the 3rd quarter worth about $25,955,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Trading Up 0.9 %

Shares of LNTH stock opened at $91.94 on Friday. Lantheus has a 12-month low of $50.20 and a 12-month high of $126.89. The company has a market cap of $6.39 billion, a price-to-earnings ratio of 15.30 and a beta of 0.45. The stock has a 50 day simple moving average of $96.63 and a 200-day simple moving average of $98.18.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.